Honest Facts On The Neratinib Successes

Sample size calculations RVX-208 All sample size calculations have been performed using SAS PROC POWER. Decrease in delirium Our sample size calculations are based on the anticipated delirium incidence and effect size for our primary end point analysis. On the basis of results of a previously published meta-analysis of four studies investigating the use of BIS-guided anaesthetic administration, we conservatively assume an incidence of postoperative delirium in the routine anaesthesia care group of 25%.29 We performed a sample size sensitivity analysis and calculated different scenarios with different values for the delirium incidence in the intervention arm and corresponding power (80%, 90% and 95%). With a two-sided �� 95% power to detect an absolute decrease in delirium incidence ��9%, >90% power to detect a decrease in delirium incidence ��8% and >80% power to detect a decrease in delirium incidence ��7%. With a 7% decrease in delirium incidence, the 95% CI would be ?3�C12%. Even a 3% decrease in delirium incidence would be clinically important, suggesting that delirium would be prevented in one out of every 33 at risk patients who received EEG guidance of general anaesthesia. Health-related quality of life The overall sample size of our study is defined through estimations Neratinib of the primary outcome (delirium). For secondary analyses, we assume that ?80% of our trial population (?1000 participants) will have completed the trial and the 1-year follow-up survey. With this sample size of 1000, we can detect a difference of 0.5 points (SD of 2.5) in the mean change of Physical Health Score from baseline to 1?year between the intervention and usual care group with a power of >80% and a two-sided �� level of pBMS-777607 supplier falls at 1-year in the routine anaesthesia care group of 40%.110 With a sample size of 1000, we will have >80% power to detect an absolute risk reduction of 12% between the EEG-guided and the usual care group at a two-sided �� level of p